Abstract. During 1993 through 1996, 2,313 cases of Rocky Mountain spotted fever (RMSF) were reported to the Centers for Disease Control and Prevention (CDC) by 42 states and the District of Columbia through the National Electronic Telecommunications System for Surveillance (NETSS). During this same interval, 1,752 case report forms (CRFs) were submitted to CDC and 1,253 (70%) of the cases were categorized as confirmed RMSF by laboratory testing. On the basis of analyses performed with NETSS data, the average annual RMSF incidence during 1993-1996 was 2.2 cases per million persons; the incidence rose from 1.8 in 1993 to 3.3 per million persons in 1996. Incidence for confirmed cases was highest among children 5-9 years of age (3.7 per million) and lowest among individuals older than 70 years of age (1.4 per million). The south Atlantic region accounted for the largest proportion of confirmed cases (52%). The case-fatality rate was highest among persons 70 years of age and older (9.0%) and lowest among adults 40-49 years of age (0.6%).
INTRODUCTION
Rocky Mountain spotted fever (RMSF), the most commonly fatal tick-borne disease in the United States, is a febrile vasculitic illness caused by infection with Rickettsia rickettsii. 1 This rickettsial species is primarily transmitted to humans by the American dog tick (Dermacentor variabilis) or the wood tick (Dermacentor andersoni). 2 Approximately 2-14 days after a bite from an infected tick, patients with RMSF typically develop sudden onset of fever, headache, and myalgia, followed several days later by a characteristic rash that commonly begins on the wrists, ankles, and forearms and then spreads centripetally to involve the trunk. 3 Biochemical abnormalities and coagulopathies are often observed and severe manifestations of the illness may include meningoencephalitis, myocarditis, adult respiratory distress syndrome (ARDS), and renal failure. 3, 4 The illness, which can occur throughout most of the continental United States, is most common in the southeast and south-central states. 1 Although the disease was originally described in the Rocky Mountain region in the late 1800s and early 1900s, 5 far fewer cases are now reported from that region than from the southeastern United States. 6 Rocky Mountain spotted fever is a nationally notifiable disease and two complementary systems are used to report RMSF cases to the Centers for Disease Control and Prevention (CDC). Cases submitted through the National Electronic Telecommunications System for Surveillance (NETSS) are reported to state health departments by physicians and other personnel working in clinics and hospitals. 7 Individual state health departments compile the data weekly and report to CDC the number of RMSF cases in their state. The second reporting system uses a standard RMSF case reporting form (CRF) that provides more detailed information on the epidemiologic context, clinical history, and laboratory test results of individual RMSF cases. The CRFs are submitted by health care providers to their state health departments and then sent to the CDC. More RMSF cases are reported by NETSS than through CRF submissions. 1 This study describes RMSF cases reported to CDC during the years 1993 through 1996. Data obtained by NETSS and through review of CRFs are summarized and analyzed with regard to the current status and long-term trends in RMSF reporting in the United States.
MATERIALS AND METHODS
Data obtained through NETSS have been used as the reference standard for calculating incidence of RMSF in the United States. 7 Incidence rate is defined as the number of RMSF cases during the specified period per million persons, based on the US Census Bureau population data. 8, 9 States were grouped in geographic regions by using standard census divisions, and incidence of RMSF was determined by region, state, county, and age group, for the study period. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated by Poisson regression analysis. 10 Cases reported to the CDC by CRFs, were categorized as confirmed, probable, and unconfirmed. A confirmed RMSF case required signs and symptoms compatible with disease (e.g., fever, headache, and petechial rash), and at least one confirmatory laboratory finding. Criteria for laboratory confirmation based on serology included a four-fold or greater change in antibody titer to R. rickettsii antigen between acute-and convalescent-phase serum specimens measured by indirect immunofluorescence assay (IFA), complement fixation (CF), latex agglutination (LA), microagglutination (MA), or indirect hemagglutination assay (IHA). In addition, criteria for laboratory confirmation of RMSF included use of polymerase chain reaction (PCR) assays with specific primers for R. rickettsii to produce an amplicon of DNA, demonstration of rickettsial antigens by immunostaining of biopsy or autopsy tissues, or isolation of R. rickettsii from clinical specimens. A probable RMSF case was defined as a clinically compatible case with a single IFA serologic titer of Ն 64 or a single CF titer of Ն 16 or other supportive serologic finding (four-fold rise in titer or a single titer of Ն 320 by Proteus OX-19 or OX-2, or a single titer of Ն 128 by an LA, IHA, or MA test). Reports not meeting these criteria were considered unconfirmed.
Characteristics of confirmed and probable cases derived from CRFs for 1993-1996 were combined and analyzed. This included analyses of age, sex, history of tick bite, recent travel, month of onset of clinical symptoms, hospitalization, symptoms, results of diagnostic testing, and outcome (death or recovered). Denominators differ by variable, since data were missing on some reporting forms from the states. Casefatality ratios were calculated from reports of confirmed RMSF cases for which patient outcome was specified; 8.6% of CRFs did not include information about patient outcome. For proportions based on information from CRFs with missing data, the denominator used in analyses is provided.
RESULTS
From 1993 through 1996, 2,313 cases of RMSF were reported to CDC through NETSS, and 1,752 completed CRFs were received. From the CRFs, 72% (1,253) of the cases were categorized as confirmed RMSF. The annual incidence of RMSF in the United States, from data reported through NETSS, decreased steadily from a high in 1981 of 5.2 cases per million to a low in 1993 and 1994 of 1.8 RMSF cases per million ( Figure 1 ; Table 1 ). The annual incidence increased to 2.3 cases per million in 1995 and 3.3 cases per million in 1996 (Table 1) .
During 1993-1996, cases of RMSF from 42 states were reported through NETSS (Table 2) . North Carolina and Oklahoma reported the most RMSF cases and had the highest state incidences; the incidence rate for North Carolina was significantly greater than that for Oklahoma (RR ϭ 1.7, 95% CI ϭ 1.4, 2.0). Together these two states accounted for 35% of the total number of US cases reported through NETSS. The incidence for the south Atlantic region (52% of the total cases from eight states and Washington DC) was significantly higher (RR ϭ 1.3, 95% CI ϭ 1.2, 1.5) than that for the next highest region (east south central; 14% of total cases from four states). The incidences for most states in these two regions were above the overall US average annual incidence of 2.2 per million population (Figure 2 ), while only six other states (Arkansas, Missouri, Montana, Oklahoma, South Dakota, and Wyoming) reported values higher than the US average. In some instances the actual number of RMSF cases reported in a state was relatively small, but the incidence was high due to the low population size (e.g., Wyoming with 24 cases but an incidence of 12.6 per million population). A few cases of RMSF were reported from locations where the disease is uncommon (e.g., Nevada, Arizona, and New Mexico). However, since travel history data were not provided, it is uncertain whether these instances represent autochthonous cases or cases imported from states where RMSF is known to be endemic.
The incidence of RMSF within states varied by county (Figure 2 ). Counties reporting RMSF were widely distributed throughout states in the mid-Atlantic region (e.g., North Carolina), south central region (e.g., Oklahoma), and some western states (e.g., Wyoming). At the margins of the endemic range of RMSF, the distribution of affected counties appeared more focal (e.g., New York, Florida, and Idaho).
For 507 (43%) of the RMSF cases confirmed through review of CRFs, onset of symptoms occurred during May and June, and 1,063 (92%) of cases occurred during the months of April through September (Figure 3) . However, confirmed cases were reported in every month of the year, and 24 (2.1%) confirmed cases were reported by 14 states (Arkansas, Florida, Illinois, Iowa, Maryland, Michigan, Missouri, New Jersey, New York, North Carolina, Oklahoma, South Carolina, and Tennessee) during the months of December through February. Tick attachment within the 14 days prior to illness was reported by 629 of 1,051 (60%) of the confirmed cases of RMSF.
The average annual incidence rate of RMSF using NETSS data, was highest among children 5-9 years of age (3.7 cases per million) and lowest among individuals 70 years of age Figure 4 ). The overall casefatality ratio, based on CRFs, was highest among individuals 70 years of age and older (9.0 %) and lowest among adults 40-49 years of age (0.6 %; Figure 4 ). Most (690/1,228; 56%) of the confirmed cases were in males. Cases occurred mostly among whites (1,006/1,141; 88%), followed by cases among blacks (n ϭ 76; 7%). Fifty-nine (5%) cases occurred among other races.
Fever (904/1,112; 81%) and headache (838/1,045; 80%)
were the most common symptoms reported for confirmed cases, followed by myalgia (817/1,023; 80%), and rash (739/ 1,122; 66%). The triad of fever, headache, and rash was present in 44% (447/1,017) of the confirmed cases. Of 1,166 confirmed cases, 604 (52%) required hospitalization; 27 deaths attributable to RMSF were reported during this period. The case-fatality ratio was 2.4% for the entire period and varied between 4.7% in 1993 and 1.2% in 1996. For the 4-year interval whites had a lower case-fatality ratio (24/931; 2.6%) than that for blacks (3/70; 4.3%), although the difference was not statistically significant (RR ϭ 0.6, 95% CI ϭ 0.2, 2.0).
DISCUSSION
Although the incidence of RMSF declined steadily over the last two decades, 1, 6 a two-year reversal in this trend was observed in 1995 and 1996. Changes in incidence of RMSF are difficult to interpret since reporting can be influenced by various epidemiologic circumstances, changes in medical care, or by artifacts in surveillance systems. Although surveillance mechanisms used by the CDC have not changed appreciably since 1981, changes in the vigilance by which individual states report complete and accurate information will affect summary statistics. Although the percent of RMSF cases confirmed over the four-year study remained relatively constant (Table 1) , there were some marked differences among the proportion of confirmed cases submitted from individual states ( Table 2) . As an example, in North Carolina and Oklahoma, the two states with the highest incidences of RMSF, the percent of confirmed cases were 53% and 98%. This discrepancy reflects the predilection of some states to submit reports of all suspect RMSF cases to CDC, even when laboratory confirmation may not be available, while others submit only those they consider confirmed.
In recent years with the increases in reporting of other tick-borne diseases, such as Lyme disease and the human ehrlichioses, there have been trends for treating acute, febrile illness during ''tick season'' with antibiotics. In some locations where Lyme disease is highly endemic, trials investigating the prophylactic use of antibiotics after tick bite have been conducted, although definitive recommendations for this type of antibiotic use remain controversial. 11 The administration of antibiotics early in the course of RMSF (or the ehrlichioses) can blunt the antibody response and may preclude a definitive diagnosis of RMSF on the basis of the most widely available serologic tests. 12, 13 Also, many patients will not have detectable antibody during their first week of illness; when death occurs during this early phase, an accurate diagnosis may depend on detection of organisms in specimens obtained at autopsy. 14 All of these factors contribute to underreporting of RMSF and an under-appreciation of mortality attributable to this disease. In addition to the issues related to diagnosis of the disease, a range of environmental and ecologic factors have been implicated in the annual variation of reported numbers of RMSF cases. 15 Additionally, experiments have demonstrated a lethal effect of R. rickettsii on one of its primary tick vectors (D. andersoni) during both transtadial and transovarial transmission, suggesting that some of the accepted maintenance mechanisms and ecologic associations of this bacterium with its vector and vertebrate hosts require reassessment. 2 The clinical and epidemiologic features of RMSF described in this paper are consistent with those presented in previous surveillance reports. 1, 6, 16 Rocky Mountain spotted fever is most commonly reported in children, males, and whites. Although children less than 10 years of age have the highest incidence of disease, persons over 60 years of age are the most likely to die of the illness. Variation of agespecific mortality has been partially attributed to a delay in diagnosis and treatment, as younger patients may develop rash earlier than elderly patients and receive appropriate treatment sooner. 17, 18 As in a previous report, whites tended to have a lower case-fatality ratio than that for blacks, 1 perhaps because of earlier detection of a rash in lighter-skinned persons. As in other surveillance reports, fever and headache were the most common symptoms reported, described in 80% to 90% of patients.
Although the number of deaths and the death to case ratio for RMSF have declined dramatically since the advent of effective antibiotics, 19 the successful treatment for RMSF depends largely on clinical acumen and prompt initiation of antibiotic therapy. The months of spring and summer constitute the ''tick season'' and RMSF should be considered in any febrile individual residing in, or with a travel history to an RMSF-endemic location, particularly in those with a history of tick bite.
